Skip to main content
Literatur
1.
2.
Zurück zum Zitat Callhoff J et al (2014) Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis (published online first) Callhoff J et al (2014) Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis (published online first)
3.
Zurück zum Zitat Dougados M et al (2014) Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 66:2091–2102CrossRefPubMed Dougados M et al (2014) Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 66:2091–2102CrossRefPubMed
4.
Zurück zum Zitat Haibel H et al (2008) Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo- controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 58:1981–1991CrossRefPubMed Haibel H et al (2008) Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo- controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 58:1981–1991CrossRefPubMed
5.
Zurück zum Zitat van der Heijde D et al (2011) (Second) Update of the ASAS recommendations on the use of TNF-blockers in ankylosing spondylitis. Ann Rheum Dis 70:905–908CrossRefPubMed van der Heijde D et al (2011) (Second) Update of the ASAS recommendations on the use of TNF-blockers in ankylosing spondylitis. Ann Rheum Dis 70:905–908CrossRefPubMed
6.
Zurück zum Zitat Landewé R et al (2014) Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 73:39–47CrossRefPubMedCentralPubMed Landewé R et al (2014) Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 73:39–47CrossRefPubMedCentralPubMed
7.
Zurück zum Zitat Sieper J et al (2013) Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 72:815–822CrossRefPubMedCentralPubMed Sieper J et al (2013) Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 72:815–822CrossRefPubMedCentralPubMed
Metadaten
Titel
Therapieoptionen bei der nicht-radiologischen axialen Spondyloarthritis (nr-axSpA)
NSAR und TNF-Blocker
verfasst von
Prof. Dr. Michael Schirmer
Publikationsdatum
01.03.2015
Verlag
Springer Vienna
Erschienen in
rheuma plus / Ausgabe 1/2015
Print ISSN: 1868-260X
Elektronische ISSN: 2191-2610
DOI
https://doi.org/10.1007/s12688-014-0015-x

Weitere Artikel der Ausgabe 1/2015

rheuma plus 1/2015 Zur Ausgabe

Brief des Herausgebers

Nur die Veränderung hat Bestand